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Abstract
Background: Repeated mild traumatic brain injuries, such as concussions, may result in cumulative brain damage,
neurodegeneration and other chronic neurological impairments. There are currently no clinically available treatment
options known to prevent these consequences. However, growing evidence implicates neuroinflammation and
oxidative stress in the pathogenesis of repetitive mild brain injuries; thus, these may represent potential therapeutic
targets. Progesterone has been demonstrated to have potent anti-inflammatory and anti-oxidant properties after
brain insult; therefore, here, we examined progesterone treatment in rats given repetitive mild brain injuries via the
repeated mild fluid percussion injury model.
Methods: Male Long-Evans rats were assigned into four groups: sham injury + vehicle treatment, sham
injury + progesterone treatment (8 mg/kg/day), repeated mild fluid percussion injuries + vehicle treatment,
and repeated mild fluid percussion injuries + progesterone treatment. Rats were administered a total of three injuries,
with each injury separated by 5 days. Treatment was initiated 1 h after the first injury, then administered daily for a
total of 15 days. Rats underwent behavioural testing at 12-weeks post-treatment to assess cognition, motor function,
anxiety and depression. Brains were then dissected for analysis of markers for neuroinflammation and oxidative stress.
Ex vivo MRI was conducted in order to examine structural brain damage and white matter integrity.
Results: Repeated mild fluid percussion injuries + progesterone treatment rats showed significantly reduced cognitive
and sensorimotor deficits compared to their vehicle-treated counterparts at 12-weeks post-treatment. Progesterone
treatment significantly attenuated markers of neuroinflammation and oxidative stress in rats given repeated mild fluid
percussion injuries, with concomitant reductions in grey and white matter damage as indicated by MRI.
Conclusions: These findings implicate neuroinflammation and oxidative stress in the pathophysiological aftermath of
mild brain injuries and suggest that progesterone may be a viable treatment option to mitigate these effects and their
detrimental consequences.
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Background
Mild traumatic brain injuries (mTBI), including concus-
sions, are a common medical problem worldwide [1].
mTBI is defined as a complex pathophysiological process
induced by traumatic biomechanical forces to the brain
and often occurs in motor vehicle accidents, assaults,
slips, and falls and in combative sports and military set-
tings [1]. Although a patient will typically recover within
hours to weeks after a single mTBI [1, 2], there is grow-
ing evidence that repeated mTBI (rmTBI) can have
cumulative and persisting neurological consequences.
For example, rmTBI has been associated with chronic
cognitive impairments and an increased risk of depression
[3–5]. Furthermore, rmTBI has been linked with a num-
ber of neurodegenerative conditions, such as chronic
traumatic encephalopathy (CTE), and is implicated in
connection with severe cognitive, emotional and motor
abnormalities [6].
Although a number of pathophysiological mechanisms
have been postulated to contribute to the cumulative
and chronic effects of rmTBI, there is growing evidence
suggesting important roles for neuroinflammation and
oxidative stress [7, 8]. Neuroinflammation is common in
TBI patients, as well as in other neurodegenerative con-
ditions associated with mTBI, including Alzheimer’s dis-
ease and motor neuron disease [8, 9]. Furthermore, both
our laboratory and others have observed elevated and
persisting neuroinflammation and oxidative stress in
experimental models of mTBI, which coincides with
progressive brain damage and chronic behavioural
abnormalities [7, 10–17].
To date, there is no clinically available intervention
known to prevent the cumulative and chronic conse-
quences of rmTBI. However, considering the possible
role of neuroinflammation and oxidative stress in the
pathogenesis of rmTBI, an intervention that targets
these secondary injury pathways may have therapeutic
effects. Progesterone (PROG), a neurosteroid originally
named due to its progestational role during pregnancy,
exerts neuroprotective effects in experimental brain
insults, including TBI [18–22]. Of particular relevance
here, PROG is safe for clinical use and has been demon-
strated to have potent anti-inflammatory and anti-
oxidant properties [18, 21, 22].
Considering the high incidence of mTBI, the cumula-
tive and chronic consequences of rmTBI, the lack of an
effective treatment strategy, as well as the likely patho-
logical involvement of neuroinflammation and oxidative
stress in the aftermath of rmTBI, we here investigated
the use of PROG treatment in a rat model of rmTBI.
With the hypothesis that PROG treatment would ameli-
orate long-term behavioural impairments via the attenu-
ation of post-traumatic inflammation and oxidative
stress, rmTBI and sham-operated rats were treated with
PROG or vehicle control and assessed after a 12-week
post-treatment recovery period. We herein report that
PROG treatment in rmTBI significantly reduced neuro-
inflammation, oxidative stress, brain damage and cogni-
tive and motor impairments.
Methods
Animals
Fifty young adult male Long-Evans hooded rats were
obtained from the animal breeding service of the
Melbourne Brain Centre and were used as subjects. All
rats were 8–12 weeks of age, weighed 250–300 g, and
were experimentally naïve prior to surgical procedures.
After surgery, all rats were housed individually under a
12 h:12 h light/dark cycle with ad libitum access to food
and water. All procedures were performed in accordance
with the guidelines of the Australian Code of Practice
for the Care and Use of Animals for Scientific Purposes
written by the Australian National Health and Medical
Research Council and were approved by the University
of Melbourne Animal Ethics Committee (#1112173).
Experimental groups and treatment
Rats were assigned into two injury groups: repeated mild
fluid percussion injury (rFPI) or sham injury (SHAM).
Rats were then further assigned to two treatment
groups: cyclodextrin 22.5 % vehicle treatment (VEH;
Sigma, Sydney, Australia) or PROG treatment (8 mg/kg
in 22.5 % cyclodextrin; Sigma, Sydney, Australia). Thus,
there were a total of four experimental groups: SHAM+
VEH, SHAM+ PROG, rFPI + VEH, and rFPI + PROG.
After each injury, the rat received an intraperitoneal
injection of their assigned treatment at 1 h post-
injury. This was followed by a daily subcutaneous in-
jection of their assigned treatment for 5 days. This
occurred after each of their three injuries. The dose
and treatment regimen was based on previous studies
reporting neuroprotective effects with PROG treat-
ment after brain injury [18–22].
Injury model
Previous studies report that a single mild fluid percus-
sion injury (FPI) in the rat induces transient behavioural
and pathophysiological changes that occur in the ab-
sence of significant neuronal loss or structural brain
damage [23–25], which is consistent with what may
occur after a single mTBI in humans [1]. Furthermore,
our laboratory [10, 11] and others [12, 24] have found
that rFPI results in cumulative and long-term neuro-
logical changes in rats that bear resemblance to those
reported in humans who have suffered rmTBI and CTE.
All of the surgical and rFPI procedures used in this
study were based on standard protocols as previously
described and used by our group [10, 11]. Briefly, rats
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were placed in a sealed Plexiglas box into which 4 %
isoflurane and 2 L/min oxygen flow was introduced for
anaesthesia. Rats were then placed in a stereotaxic frame
via ear bars, with anaesthesia maintained at 2 % isoflur-
ane and 1 L/min oxygen, and given a subcutaneous
injection of analgesic (carprofen 5 mg/kg). A craniotomy
(5 mm diameter) was performed on all rats, centred over
the following coordinates with reference to the bregma:
anterior/posterior −3.0 mm, medial/lateral 4.0 mm. A
hollow plastic injury cap was sealed over the craniotomy,
and a removable plug was inserted into the injury cap to
seal the craniotomy at all times except during mild FPI
or sham injury. Immediately after the surgery, rats were
attached to the FPI device. At the first response of a
hind limb withdrawal to a toe pinch, rats assigned to
the rFPI groups were administered a mild FPI that
was induced by a 1–1.5 atm fluid pulse to the brain.
Rats from the SHAM groups were administered a
sham injury, which involved identical procedures as
those for a FPI except that the fluid pulse was not
administered. Two subsequent injuries were per-
formed in the same manner at 5-day intervals. Apnea,
return of toe pinch reflex, and self-righting reflexes
were monitored after each of the injuries as indicators
of injury severity [10, 11, 23] (Table 1).
Behavioural testing
Behavioural testing began 12 weeks after the final day of
treatment. Testing was carried out over five consecutive
days and was completed by a researcher blinded to
experimental conditions on all 50 rats. Rats first under-
went testing in the elevated plus maze to assess anxiety-
like behaviours as previously described [10, 11, 26, 27].
Briefly, rats were placed into the maze facing an open
arm and allowed 5 min to freely explore the maze. An
overhead camera recorded behaviours, and the number
of entries into and the amount of time spent in open or
closed arms were quantified by EthoVision® Tracking
Software (Noldus™, Netherlands). A percentage score
was calculated for the time spent in the open arm, as
this is decreased in rats experiencing heightened anxiety
[26, 27]. Entries into the closed arm were calculated as a
measure of locomotion and were defined by all four
paws having entered the arm [11].
Rats were next tested in the open field to assess
locomotor and anxiety-like behaviours as previously
described [10, 11, 23]. Briefly, the rats were individu-
ally placed in a circular open arena (100 cm diameter,
20 cm high wall) and allowed to freely explore for
10 min. An overhead video camera recorded behav-
iour, and EthoVision® software was used to calculate
the total distance travelled (cm), as well as the time
spent and number of entries into the inner area
(50 cm diameter) of the open field.
To assess cognition, water maze testing was conducted
as previously described [27]. A circular pool (163 cm
diameter) was filled with tap water (29 °C), and a hidden
acrylic escape platform (10 cm diameter) was submerged
2 cm below the water surface in one of the quadrants of
the pool. Water maze testing involved an acquisition ses-
sion (day 1) and a reversal session (day 2), with each day
consisting of ten trials with a maximum time of 60 s given
for each trial. Each trial began at one of the four locations
in the pool (north, south, east or west) that were pseudo-
randomized to prevent sequential starts from the same
location. A trial began when a rat was placed in the pool
next to and facing the pool wall and ended when either
the rat reached and stood on the hidden platform or 60 s
elapsed, at which point the experimenter would guide the
rat onto the platform. An overhead video camera recorded
behaviour and EthoVision® software used to calculate the
search time to locate the platform and the number of dir-
ect and circle swims as measures of spatial place memory
[27]. Swim speed (cm/s) was also calculated as a measure
of motor ability. All the settings for the acquisition session
and reversal session were the same, with the exception of
the escape platform, which was moved to the opposite
quadrant [11, 28].
The beam task was used to assess sensorimotor func-
tion as previously described [27, 28]. During beam train-
ing, rats were given five trials to traverse a 100-cm-long
beam with a width of 4 cm and an additional five trials
to traverse a 100-cm-long beam with a width of 2 cm.
Beam testing occurred 24 h after beam training and con-
sisted of ten trials on the 2-cm-wide, 100-cm-long beam.
Table 1 Acute post-injury outcomes
Injury 1 Injury 2 Injury 3
Hind limb Self-righting Hind limb Self-righting Hind limb Self-righting
SHAM + VEH 0 ± 0 98.9 ± 5.2 0 ± 0 98.1 ± 6.5 0 ± 0 93.3 ± 5.0
SHAM + PROG 0 ± 0 101.8 ± 5.8 0 ± 0 99.2 ± 6.4 0 ± 0 96.1 ± 7.4
rFPI + VEH 0.83 ± .56* 149.2 ± 13.4* 2.08 ± .96* 159.9 ± 13.7* 1.25 ± .90* 160.2 ± 9.6*
rFPI + PROG 1.15 ± .61* 158.7 ± 13.0* 1.54 ± .67* 150.2 ± 10.5* 1.54 ± .87* 154.5 ± 8.0*
Regardless of the assigned treatment, rFPI resulted in worse acute injury severity outcomes as indicated by increased hind limb withdrawal and self-righting reflex
times compared to the SHAM groups. There was no apnea observed after any of the injuries
*rFPI significantly greater than sham-injured groups, p < 0.001
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A maximum of 60 s was permitted for each trial.
Traverse times and the number of slips and falls were
scored [10]. Rats that fell off the beam were scored with
the maximum time.
Depression-like behaviour was assessed using the
forced swim task [12, 29]. Rats underwent forced swim
training on day 4 of behavioural testing. For training, the
rat was placed in the forced swim apparatus, which
consisted of a clear cylinder (diameter = 30 cm, height =
40 cm) filled to a depth of 30 cm with water at 25 °C for
15 min. Forced swim testing occurred 24 h after forced
swim training. Each rat was placed in the apparatus for
5 min. Behaviour was recorded by a video camera from
a horizontal angle and later scored to calculate the time
each rat spent immobile, the time spent escaping and
the time spent swimming. Only behaviours that per-
sisted longer than 2 s were scored.
Brain tissue preparation
One day after completion of behavioural testing, rats
were killed to obtain either fresh brain tissue for meas-
urement of lipid peroxidation (n = 5/group) or fixed
brain tissue for MRI and immunofluorescence analyses
(n = 7–8/group). For fresh tissue collection, rats were
deeply anaesthetised and decapitated, and the ipsilateral
cortex was rapidly dissected. Fresh tissue was then
immediately frozen in liquid nitrogen and later stored
at −80°C. For fixed brain tissue collection, rats were
deeply anaesthetised and transcardially perfused with
ice-cold phosphate-buffered saline followed by 4 %
paraformaldehyde in phosphate-buffered saline. Whole
brains were removed and stored in 4 % paraformalde-
hyde at 4 °C until MRI scanning. After MRI, fixed
brains were embedded in paraffin for immunofluores-
cence procedures [23, 30, 31]. All analyses were con-
ducted by investigators blinded to injury or treatment
group allocation.
MRI data acquisition
A 4.7 T Bruker Avance III scanner (Bruker™ Biospec®,
USA) with a 30-cm horizontal bore was used for MRI
scanning. The magnet was fitted with a BGA12S2 gradi-
ent set and actively decoupled volume transmit and
four-channel surface receive coils for imaging. Ex vivo
brains were placed in 15-ml falcon tubes filled with
paraformaldehyde and taped to the surface coil to be
scanned.
The protocol for scanning consisted of a three-plane
localizer sequence followed by multi-slice axial, coronal
and sagittal images to accurately determine the orienta-
tion of the rat brain. A rapid acquisition with relaxation
enhancement (RARE) sequence was used to acquire T2-
weighted images with the following imaging parameters:
RARE factor = 8, effective echo time = 36 ms, repetition
time = 12 s, matrix size = 144 × 72, field of view = 28.8 ×
14.4 mm2, number of axial slices = 60, isotropic spatial
resolution = 200 × 200 × 200 μm3, and number of excita-
tions = 32.
A 3D echo planar sequence was used to perform
diffusion-weighted imaging with the following parame-
ters: repetition time = 2500 ms, field of view = 32 × 16 ×
12 mm3, echo time = 62 ms, matrix size = 128 × 64 × 48,
and isotropic resolution = 250 × 250 × 250 μm3. Diffu-
sion weighting was performed with the diffusion
duration (δ) = 7 ms, the diffusion gradient separation
(Δ) = 20 ms, and b value = 8000 s/mm2 in 81 non-
collinear directions with 9 non-diffusion images (b0).
MRI analysis
MRI analysis was completed by two researchers, both of
whom were blinded to the experimental conditions. As
previously described [27, 31, 32], one researcher used
FSL View (Analysis group, Oxford, UK) to manually
trace eight a priori regions of interest (ROIs) on T2-
weighted images. ROIs included the ipsilateral and
contralateral hippocampus, cortex, corpus callosum and
lateral ventricles. ROIs were traced on consecutive cor-
onal MRI slices, and only slices containing hippocampus
were analysed. The second researcher confirmed the
accuracy of the ROI traces and processed the MRI data.
The total volume for each ROI was calculated using
MATLAB® (The MathWorks®, Natick, MA, USA).
Diffusion tensor imaging (DTI) analysis was conducted in
order to assess the integrity of the corpus callosum, a major
white matter tract commonly affected by TBI [27, 32]. ROI
masks of the corpus callosum were transformed into the
diffusion image space using Advanced Normalization Tools
(ANTs, http://stnava.github.io/ANTs/), and mean DTI
measures including fractional anisotropy (FA), mean diffu-
sivity, radial diffusivity and axial diffusivity were calculated
using the FSL diffusion toolbox (FDT, http://fsl.fmrib.ox.a
c.uk/fsl/fslwiki/FDT) and MATLAB® software.
Immunofluorescence analysis
As previously described [31–33], immunofluorescence
staining and analysis was performed to assess neuroin-
flammation. Three 4-μm coronal sections from each rat
were selected and obtained at the level of injury
(−3.0 mm bregma). The sections were deparaffinized
and rehydrated [31, 33, 34], then immersed in 0.21 %
citric acid buffer (pH 6.0) at boiling temperature in a
1250-W microwave oven for 15 min for antigen re-
trieval. The sections were then permeabilized with 0.1 %
Triton X-100 in phosphate-buffered saline for 10 min
and covered in 5 % bovine serum albumin for 60 min at
room temperature, followed by incubation with primary
antibodies overnight at 4 °C [31, 33]. Anti-GFAP anti-
body (1:500, rabbit Dako®, Carpentaria, CA, USA) was
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used as a marker for reactive astrocytes, which have in-
creased expression of GFAP, enlarged cytoplasm and
bear elongated and hypertrophic processes [35]. Anti-
CD68 (1:500, mouse Abcam®, Cambridge, UK) antibody
was used as a marker for activated microglia/macro-
phages with an amoeboid morphology/phagocytic func-
tion [36–38]. The sections were washed in PBS then
incubated for 60 min with goat anti-rabbit secondary
antibody (1:800, Alexafluor® 488, USA), for GFAP stain-
ing, or goat anti-mouse secondary antibody (1:500,
Alexafluor® 488, USA), for CD68 staining. The sections
were washed again and incubated at room temperature
with Sudan Black for 10 min. Slides were then dehy-
drated and coverslipped [31, 33].
For analysis, photomicrographs of GFAP and CD68 stain-
ing were captured using a Carl Zeiss® fluorescence
Axioplan-2 microscope at ×20 magnification, under fixed
exposure times and light illumination settings to ensure ob-
jectivity in image quality and position. One photomicro-
graph of the most immunoreactive position in the
ipsilateral cortex for a total of three photomicrographs for
each rat was captured, for a total of three photomicro-
graphs per rat.
GFAP was quantified using the threshold function on
ImageJ software (NIH, USA) to create a semi-quantitative
index of immunoreactivity by summing the immunoposi-
tive area within the digital image, expressed in square
micrometers [31, 33]. CD68-positive cells were manually
counted on each photomicrograph, and the numbers from
the three sections were summed for each rat [31, 33].
Measurement of lipid peroxidation
The relative levels of malondialdehyde (MDA), an indi-
cator of lipid peroxidation, were measured using a thio-
barbituric acid reactive substances (TBARS) assay as
previously described [11, 28]. Tissue samples were pre-
pared as directed from the MDA assay kit (MAK085;
Sigma-Aldrich®, St Louis, MO, USA).
Statistical analysis
SPSS 21.0 was used for all statistical analyses. Water maze
search time was analysed using a repeated measures ana-
lysis of variance (ANOVA) with injury and treatment as
between-subjects factors and trial as the within-subjects
factors. Two-way ANOVAs, with injury and treatment as
between-subjects factors, were used for all other analyses.
Bonferonni post hoc comparisons were used when appro-
priate. Statistical significance was set at p ≤ 0.05.
Results
PROG treatment reduces cognitive and sensorimotor
deficits in rFPI
ANOVA indicated a significant injury × treatment inter-
action on the measure of direct and circle swims during
water maze testing (F1, 46 = 4.133, p < 0.05, Fig. 1a). Post
hoc analysis found that rFPI + VEH rats performed fewer
direct and circle swims than all other groups (p < 0.05),
whereas the rFPI + PROG group did not significantly dif-
fer from either of the SHAM groups. There was also a
significant treatment effect found for the measure of
search time (F1, 46 = 4.387, p < 0.05, Fig. 1b), indicating
that rats treated with PROG located the platform faster
than those treated with VEH. Significant effects for injury
were also found for both direct and circle swims (F1, 46 =
8.474, p < 0.01) and search time (F1, 46 = 5.607, p < 0.05).
There were no statistically significant differences on the
measure of swim speed (Fig. 1c), suggesting that motor
impairments did not confound the cognitive measures.
ANOVA revealed a significant injury × treatment
interaction on the measure of slips and falls on the beam
task (F1, 46 = 51.533, p < 0.05, Fig. 2a). Post hoc analysis
indicated that the rFPI + VEH group had significantly
more slips and falls than all other groups (p < 0.01),
whilst the rFPI + PROG group did not significantly differ
from either of the SHAM groups. There were no statisti-
cally significant findings on the measurement of average
traverse times (Fig. 2b).
There were no statistically significant findings for
the elevated plus maze, open field or forced swim
task (all p > 0.05).
PROG treatment reduces brain damage in rFPI
MRI volumetrics
As shown in the representative MRI images (Fig. 3a–d),
there was a loss of ipsilateral cortex and ipsilateral
hippocampus volumes in rFPI + VEH rats as compared
to all other groups. ANOVA revealed a significant in-
jury × treatment interaction in the ipsilateral cortex
(F1, 26 = 4.237, p < 0.05, Fig. 3e) and ipsilateral hippo-
campus (F1, 26 = 4.697, p < 0.05, Fig. 3f ). Post hoc ana-
lysis indicated a significant reduction of ipsilateral
cortex and ipsilateral hippocampus volumes in rFPI +
VEH group compared to all other groups (p < 0.01),
whereas the rFPI + PROG group did not differ signifi-
cantly from either SHAM group.
Significant treatment effects were found in the ipsilat-
eral corpus callosum (F1, 26 = 16.801, p < 0.001, Fig. 3g),
contralateral cortex (F1, 26 = 5.357, p < 0.05, Fig. 3e), and
contralateral corpus callosum (F1, 26 = 5.659, p < 0.05,
Fig. 3g), indicating that PROG-treated rats had signifi-
cantly more volume of these brain structures compared
to VEH-treated rats. There were also significant treat-
ment effects in the ipsilateral (F1, 26 = 9.626, p < 0.005,
Fig. 3h) and contralateral lateral ventricles (F1, 26 =
10.687, p < 0.01, Fig. 3h), indicating that PROG-treated
rats had smaller lateral ventricle volumes than rats
treated with VEH.
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Significant injury effects were found in the ipsilateral
corpus callosum (F1, 26 = 4.887, p < 0.05), contralateral
hippocampus (F1,26 = 5.190, p < 0.05), and contralateral
corpus callosum (F1, 26 = 9.220, p < 0.005), indicating that
rFPI rats had significantly less volume of these structures
than SHAM rats. There were also significant injury ef-
fects in the ipsilateral (F1, 26 = 11.812, p < 0.005) and
contralateral (F1, 26 = 6.727, p < 0.05) lateral ventricles in-
dicating that rFPI rats had significantly larger lateral
ventricles than SHAM rats.
DTI
The integrity of the corpus callosum, a major white mat-
ter tract commonly affected by mTBI, was assessed
using DTI. ANOVA found a significant injury × treat-
ment interaction (F1, 26 = 4.340, p < 0.05, Fig. 4e) on the
Fig. 1 PROG treatment reduces cognitive deficits after rFPI. rFPI +
VEH rats had significantly fewer direct and circle swims than all other
groups during water maze testing (a). PROG-treated groups also had
faster search times (b). There were no significant differences on the
measure of swim speed (c), suggesting that motor deficits did not
confound cognitive measures during water maze testing. Triple asterisks
significantly different than all other groups, number sign significant
treatment effect, p < 0.05
Fig. 2 PROG treatment reduces motor deficits after rFPI. rFPI + VEH rats
displayed more slips and falls compared to all other groups on the beam
task (a). There were no significant differences on the measure of average
traverse times (b). Triple asterisks significantly different from all other
groups, p< 0.05
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measure of FA in the ipsilateral corpus callosum. Post
hoc analysis found that rFPI + VEH rats had a significant
reduction in FA compared to all other groups (p < 0.01),
suggesting axonal injury. Notably, rFPI + PROG rats
were not significantly different than shams. There were
no differences in FA findings in the contralateral corpus
callosum.
In addition, significant treatment effects indicated that
VEH-treated rats had increased mean diffusivity (ipsilateral
corpus callosum, F1, 26 = 7.876, p < 0.005; contralateral cor-
pus callosum, F1, 26 = 4.313, p < 0.05; Fig. 4f), radial diffusiv-
ity (ipsilateral corpus callosum, F1, 26 = 8.127, p < 0.01;
contralateral corpus callosum, F1, 26 = 4.443, p < 0.05; Fig. 4g),
and axial diffusivity (ipsilateral corpus callosum, F1, 26 =
6.897, p < 0.05, Fig. 4h). Significant injury effects further re-
vealed that rats given rFPI also had increased mean diffusiv-
ity (ipsilateral corpus callosum, F1, 26 = 10.570, p < 0.005;
contralateral corpus callosum, F1, 26 = 10.047, p < 0.005;
Fig. 4f ), radial diffusivity (ipsilateral corpus callosum,
F1, 26 = 13.924, p < 0.001; contralateral corpus callo-
sum, F1, 26 = 14.225, p < 0.001; Fig. 4g), and axial diffusivity
(ipsilateral corpus callosum, F1, 26 = 6.001, p < 0.05; contra-
lateral corpus callosum, F1, 26 = 5.124, p < 0.05; Fig. 4h).
PROG treatment reduces neuroinflammation and
oxidative stress in rFPI
There was a significant injury × treatment interaction
for GFAP immunoreactive area in the injured cortex
Fig. 3 PROG treatment attenuates brain atrophy after rFPI. As shown in the representative T2-weighted MRI images (a–d), rFPI + VEH rats had
significantly less volume of the ipsilateral cortex (e) and ipsilateral hippocampus (f) than all other groups, whereas the rFPI + PROG group did not
significantly differ from SHAM groups. PROG-treated rats also had increased volume of the ipsilateral corpus callosum (g), contralateral corpus
callosum (g) and contralateral cortex (e) and smaller lateral ventricles (h). Rats given rFPI had reduced volume of contralateral hippocampus (f),
ipsilateral corpus callosum (g), contralateral corpus callosum (g) and larger lateral ventricles (h). Triple asterisks significantly different from all other
groups, number sign significant treatment effect, single asterisk significant injury effect, p < 0.05
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(F1, 17 = 7.642, p < 0.05, Fig. 5i). Post hoc analysis
found that rFPI + VEH rats had a significant increase
of GFAP compared to all other groups (p < 0.01),
whereas there was no difference between rFPI + PROG
and SHAM groups. As shown in Fig. 5c, rFPI + VEH rats
had densely stained and hypertrophic astrocytes with long
and overlapping processes. These findings suggest that
treatment with PROG attenuated rFPI-induced reactive
astrogliosis.
There was a significant injury × treatment interaction
for the number of CD68-positive cells in the injured cor-
tex (F1, 17 = 5.206, p < 0.05, Fig. 5j). Post hoc analysis
found that rFPI + VEH rats had significantly more
CD68-positive cells than all other groups (p < 0.05),
whereas there was no difference between rFPI + PROG
and SHAM groups. As shown in Fig. 5g, these CD68-
postive cells had an amoeboid morphology typical of
phagocytic macrophages. These findings suggest that
treatment with PROG attenuated the rFPI-induced acti-
vation of macrophages/microglia.
ANOVA found a significant injury × treatment inter-
action (F1, 13 = 7.177, p < 0.05, Fig. 5k) in MDA, an indi-
cator of lipid peroxidation. Post hoc analysis found that
rFPI + VEH rats had significantly higher levels of MDA
than all other groups, including the rFPI + PROG group
(p < 0.05). However, it was also found that rFPI + PROG
Fig. 4 PROG treatment mitigates corpus callosum injury after rFPI. As shown in the representative fractional anisotropy (FA) maps (a–d), rFPI +
VEH rats had significantly reduced mean FA in the corpus callosum (e) compared to all other groups, whereas the rFPI + PROG group did not
significantly differ from SHAM groups. f PROG-treated rats had decreased mean diffusivity in the ipsilateral and contralateral corpus callosum,
whereas rFPI rats had increased mean diffusivity in the ipsilateral and contralateral corpus callosum. g PROG-treated rats had decreased radial diffusivity
in the ipsilateral and contralateral corpus callosum, whereas rFPI rats had increased radial diffusivity in the ipsilateral and contralateral corpus callosum.
h PROG-treated rats had decreased axial diffusivity in the ipsilateral corpus callosum, whereas rFPI rats had increased axial diffusivity in the ipsilateral
and contralateral corpus callosum. Triple asterisks significantly different than all other group, number sign significant treatment effect, single asterisk
significant injury effect, p < 0.05
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rats had significantly higher levels of MDA than both
SHAM groups (p < 0.05), suggesting that treatment with
PROG reduced rFPI-induced lipid peroxidation but did
not prevent it.
Discussion
Repetitive mild brain injuries can result in cumulative
brain damage and neurodegeneration that has been
linked to neuroinflammation and oxidative stress, and
there are currently no clinically available treatment op-
tions known to mitigate these effects in rmTBI patients.
Therefore, here, we conducted the first study to evaluate
the potential of PROG to reduce neuroinflammation and
oxidative stress, and the associated neurodegeneration
and neurological impairments, in experimental rmTBI.
Rats given rFPI and treated with VEH had increased
neuroinflammation and oxidative stress, with concomi-
tant damage to grey and white matter brain structures,
and cognitive and motor deficits at 12 weeks post-injury.
Importantly, rats given rFPI and treated with PROG had
significantly less neuroinflammation, oxidative stress and
brain damage, in addition to improved cognitive and
sensorimotor function compared to their VEH-treated
counterparts. These novel data demonstrate that PROG
treatment has anti-inflammatory, anti-oxidant and neu-
roprotective effects in experimental rmTBI and thus pre-
sents potential as a therapeutic intervention for the
clinical presentation of this syndrome.
The role of neuroinflammation and oxidative stress in
rmTBI
The pathogenesis of rmTBI likely involves a number of
secondary injury processes. Growing evidence, supported
by our findings here, implicates neuroinflammation and
oxidative stress as key contributing factors [7, 8]. Sus-
tained neuroinflammation, characterized by activation of
microglia and astrocytes, is known to be a key mediator of
progressive secondary injury after brain insult and other
neurodegenerative conditions [8]. With regard to mTBI,
we and others have reported transient neuroinflammation
after a single mild FPI in rats that becomes exacerbated
and sustained upon repeated insults [10–12, 23, 25, 30].
Fig. 5 PROG treatment reduces neuroinflammation and oxidative stress after rFPI. As shown in the representative images of GFAP (a–d) and CD68
(e–h) immunofluorescence staining, rFPI + VEH rats had significantly increased GFAP immunoreactive area (i) and CD68-positive cells (j), whereas the
rFPI + PROG group did not significantly differ from SHAM groups on either measure. The rFPI + VEH rats also showed significantly increased levels of
MDA, a marker of lipid peroxidation, compared to all other groups (k). Though rFPI + PROG rats had significantly less lipid peroxidation than rFPI + VEH
rats, they had significantly more lipid peroxidation than both SHAM groups. Triple asterisks significantly different than all other groups, double asterisks
significantly different than SHAM groups, p < 0.05
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Consistent with these findings, we observed astrogliosis,
as indicated by increased GFAP immunoreactivity, and
increased activated microglia and macrophages, as evi-
denced by increased CD68-positive cells with amoeboid
morphologies, in the injured cortex of rFPI + VEH rats at
12 weeks post-injury.
Once activated, astrocytes and microglia undergo mor-
phological changes. Reactive astrocytosis involves cellu-
lar hypertrophy, lengthened processes and increased
expression of GFAP [35]. Activated microglia undergo a
morphological change, taking on an amoeboid shape re-
sembling peripheral macrophages, and scavenge the
damaged CNS, performing phagocytic functions [39, 40].
Activated astrocytes and microglia produce and release a
number of pro-inflammatory mediators, including the
cytokine tumour necrosis factor-alpha (TNF-α) and
interleukin-1 beta (IL-1β) that may contribute to sec-
ondary brain damage through mechanisms such as
apoptosis [39, 40]. Activated microglia/macrophages, re-
active astrocytes and other immune cells can also pro-
duce and release reactive oxygen species, such as nitric
oxide, that contribute to oxidative stress—an imbalance
of reactive oxygen species and endogenous anti-oxidants
agents [11, 28, 39–43]. Neuroinflammatory factors such
as NF-κB, signaling downstream of TNF-α and nitric
oxide, are robustly elevated after TBI and likely contrib-
ute to oxidative stress and neuronal loss, which in turn
further exacerbate the inflammatory response [44, 45].
One consequence of oxidative stress is lipid peroxida-
tion, which involves the oxidative degradation of lipids
in cell membranes [11, 21, 28, 46]. We also detected an
increase in lipid peroxidation in rats given rFPI + VEH.
Our findings of persisting neuroinflammation and oxi-
dative stress occurred in the presence of structural brain
damage and functional impairments, which suggests a
role for these secondary injury pathways in the patho-
genesis of rmTBI. Further supporting this notion, we
found that PROG attenuated the persisting neuroinflam-
mation and oxidative stress and that these changes were
associated with decreased brain damage and improved
long-term cognitive and motor outcomes in rats given
rmTBI. These results of anti-inflammatory and anti-
oxidant effects of PROG treatment in rmTBI are consist-
ent with previous experiments in moderate to severe
TBI studies [19–22]. Whilst the exact mechanisms re-
main unclear, PROG is thought to act on inflammation
and oxidative stress both directly [47, 48] and indirectly
by the modulation of toll-like receptors and NF-κB sig-
naling with a concurrent reduction in cytokines [49, 50].
Nitric oxide has also been shown to be reduced by post-
injury treatment with PROG, possibly through the pre-
vention of inducible nitric oxide synthase, an isoform
that abundantly produces nitric oxide during secondary
injury [51, 52]. It should be noted that although rFPI +
PROG rats had significantly reduced levels of lipid per-
oxidation than the rFPI + VEH group, MDA levels were
still elevated compared to both SHAM groups. This
remaining oxidative stress may have contributed to the
relatively mild MRI-detected brain damage that was still
evident in the rFPI + PROG rats. That PROG treatment
was not able to fully negate oxidative stress may be due
to a number of reasons, including dose and duration of
the PROG treatment or the potential contribution of
other mechanisms not targeted by PROG, and requires
further exploration. For example, future experimentation
could look at a combinatorial therapy, with the addition
of agents targeting other secondary pathways.
The nature of cognitive and motor deficits after rmTBI
Spatial cognition, as assessed in the water maze [53, 54],
was shown to be impaired in rFPI + VEH rats through
the measure of direct and circle swims, consistent with
previous data [10, 11]. Direct and circle swims represent
the most efficient route to a known escape position in
the water maze, indicating that rFPI + VEH rats were
less efficient at the task than the other groups [10, 11,
53, 54]. As there were no group differences on the meas-
ure of swim speed during water maze testing, or any
anxiety-related outcomes in other tasks, the deficits
observed in the rFPI + VEH rats were likely cognitive in
nature. Notably, the rFPI + PROG group did not signifi-
cantly differ from the two SHAM groups on the measure
of direct and circle swims, suggesting that PROG was
able to preserve cognitive function after rFPI. There was
also a significant treatment effect indicating that PROG-
treated rats located the hidden platform faster than
VEH-treated rats, which further supports the notion that
PROG preserved cognitive function in the water maze.
Consistent with previous studies [10, 11], the rFPI +
VEH rats displayed significant sensorimotor deficits, as
indicated by more slips and falls on the beam task com-
pared to all other groups [55]. In contrast, the rFPI +
PROG rats did not show any significant sensorimotor
deficits relative to the SHAM groups. As there were no
differences found in average beam traverse times, nor in
other gross motor measures from the other behavioural
tasks between groups, these sensorimotor deficits occur-
ring in the rFPI + VEH rats was likely mild in nature.
Nonetheless, these findings indicate that PROG treat-
ment is able to attenuate both sensorimotor and cogni-
tive dysfunction after rFPI.
The cognitive and sensorimotor deficits in the rFPI +
VEH rats, and the preservation of these functions in the
rFPI + PROG rats, may be related to the degree of
brain damage in these animals. MRI-based volumetric
analysis of the ipsilateral cortex and ipsilateral hippo-
campus revealed significant atrophy of these struc-
tures in the rFPI + VEH rats that did not occur in the
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rFPI + PROG rats. Of particular note, the sensorimotor
cortex is situated near the FPI impact area [27, 56, 57],
and damage to the cortex and hippocampus has been
linked to cognitive and sensorimotor deficits in TBI
[27, 58–61]. DTI analyses of the corpus callosum, a
major white matter tract commonly affected by TBI
[62], showed significant diffusion abnormalities sug-
gestive of axonal injury in the rFPI + VEH group but
not in the rFPI + PROG group. Finally, a previous
study found that rats given a TBI had increased cell
proliferation and survival of immature neurons in the
dentate gyrus of the hippocampus and that PROG
treatment normalized these effects [63]. Because the
hippocampus is an important structure involved in
cognitive function, it is interesting to speculate
whether abnormalities in neurogenesis may be in-
volved in the cognitive outcomes we found here.
Taken together, it is likely that changes to each of the
abovementioned brain structures may have contrib-
uted to the behavioural findings in this study. How-
ever, further research is required to determine the
precise mechanisms underlying the functional deficits
occurring in rmTBI.
PROG as a treatment for mTBI patients?
To our knowledge, this is the first study to demonstrate
that PROG reduces neuroinflammation, oxidative stress,
brain damage and functional deficits in experimental
rmTBI, particularly in the more chronic stage of injury.
Considering that there is currently no effective treat-
ment known to reduce the detrimental long-term effects
caused by rmTBI, these findings hold important implica-
tions for the future treatment of mTBI patients. In this
study, we began PROG treatment after the first mTBI
and continued treatment until 5 days after the third in-
jury. As such, PROG treatment was given prophylactic-
ally for the second and third injuries, and this may have
contributed to the protective effects. In the clinical set-
ting, this could be comparable to a high-risk individual
(e.g., athlete or soldier) who has already suffered one
mTBI and continues treatment for the remaining dur-
ation of their high-risk activity (e.g., season or tour of
duty). As the recommended time window for PROG
treatment after a brain insult is within 2 h [64, 65], this
preventative treatment paradigm may be advantageous
within these high-risk environments. However, there are
other possible scenarios where PROG treatment may be
beneficial as a therapy for mTBI. For example, it is pos-
sible that PROG treatment acutely after a single mTBI
may improve recovery, prevent post-concussion syn-
drome or reduce vulnerability to a second brain insult.
PROG treatment in the chronic stages post-mTBI may
also be beneficial for the minority of mTBI patients who
do suffer a persisting post-concussion syndrome or for
individuals who have suffered past mTBIs and have per-
sisting neuroinflammation. Of particular interest, a re-
cent study utilizing PET imaging found that retired NFL
players with a history of mTBI had increased binding of
[11C]DPA-713 to translocator protein, an indicator of
neuroinflammation, as well as concomitant brain atro-
phy [66]. Therefore, treatment with PROG at chronic
stages post-injury should also be explored, and the use
of neuroinflammatory biomarkers (e.g., PET) could
allow for a more precise medical approach. Taken to-
gether, there are a number of clinical mTBI settings
where PROG treatment may be applicable; however,
future studies are clearly required to investigate
whether PROG treatment is beneficial in these vari-
ous scenarios and to determine the optimal thera-
peutic windows and dose.
Importantly, PROG has a long history of clinical use
and safe administration in both male and female patients
[67, 68]. This includes recent phase III clinical trials with
PROG treatment in severe TBI patients [69, 70]. Unfor-
tunately, these trials did not show improvement on the
Glascow Outcome Scale and Extended Glascow Out-
come Scale at 3 and 6 months post-injury in moder-
ate and severe TBI patients treated acutely with
PROG [69, 70]. Though these trials failed to demonstrate
efficacy for PROG treatment in more severe TBI, the au-
thors of these studies raised a number of limitations that
are important to consider including limited/insensitive
outcome measures, unidimensional TBI characterization
approaches (e.g., Glascow coma scale) and the heterogen-
eity of severe TBI [69–73]. It has also been suggested that
sub-optimal doses were used in the PROG trials [71–73],
which highlight the need to measure PROG levels in fu-
ture clinical and pre-clinical studies. It is also worth
speculating whether PROG, which targets secondary
injury processes, may be better suited to attenuate re-
sponses in the more subtle pathological environment
occurring in mTBI and rmTBI, where there is little to
no irreversible primary injury. This is in contrast to
moderate and severe TBI, where the primary injury
incurred at the moment of impact contributes to a
large part of the deficits seen in patients, and initiates
a robust secondary injury response resulting in con-
siderable swelling, cell death and tissue loss [74].
Conclusions
Here, we examined whether PROG treatment in rats
given rmTBI improved long-term outcomes. Proges-
terone treatment significantly attenuated markers of
neuroinflammation and oxidative stress in rats given
rmTBI, with concomitant reductions in behavioural
impairments and brain damage. These findings further
implicate neuroinflammation and oxidative stress in
the pathophysiological aftermath of mild brain
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injuries. Furthermore, the proven safety and limited
negative side effects of PROG, along with our findings
here, suggest that PROG may be a viable treatment
option within the context of mTBIs and their more
chronic consequences.
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